Skip to main content

Andrew Berchuck, MD

Andrew Berchuck, MD
James M. Ingram Professor of Gynecologic Oncology
Campus Mail: 25171 Morris Bldg, Durham, NC 27710
Phone: (919) 684-3765
Email: berch001@mc.duke.edu

Dr. Andrew Berchuck is Director of the Duke Division of Gynecologic Oncology and holds the James M. Ingram Distinguished Professorship. He is a practicing oncologist who is actively involved in the surgical and chemotherapy management of women with ovarian, endometrial and lower genital tract cancers. This includes minimally invasive laparoscopic surgical approaches. He also has developed a research program that focuses on the molecular-genetic alterations involved in malignant transformation of the ovarian and endometrial epithelium. He has published over 300 peer-reviewed papers in these areas. The objectives of his research include 1) identification of ovarian cancer susceptibility polymorphisms through a population-based case-control molecular epidemiologic study, and 2) use of genomic approaches  to elucidate the molecular heterogenetity of ovarian cancer. Thirty fellows and residents have worked in his lab, several of whom are now funded investigators. His research efforts have been recognized nationally and he has received awards for best oral presentation at the annual meetings of both the Society of Gynecologic Oncology and the International Gynecologic Cancer Society. Dr. Berchuck was awarded the Barbara Thomason Ovarian Cancer Research Professorship by the American Cancer Society in 2006. He has served as editor of several books in the field including Principles and Practice of Gynecologic Oncology. Dr. Berchuck also has a major commitment to national activities, and was President of the Society of Gynecologic Oncology in 2008. He served as chair of the scientific advisory committee of the Ovarian Cancer Research Fund (http://www.ocrf.org) in New York City. Finally, he is also head of the steering committee of the international Ovarian Cancer Association Consortium (OCAC), a group of 50 case-control studies that are working together to identify ovarian cancer susceptibility polymorphisms (www.srl.cam.ac.uk/consortia/ocac/index.html).

Education and Training

  • M.D., Case Western Reserve University, 1980

Research

Dr Berchuck is interested in the molecular pathogenesis of ovarian and endometrial cancer. 

View Publications

Publications

Dressman, HK, Berchuck, A, Chan, G, Zhai, J, Bild, A, Sayer, R, Cragun, J, Clarke, J, Whitaker, RS, Li, L, Gray, J, Marks, J, Ginsburg, GS, Potti, A, West, M, Nevins, JR, and Lancaster, JM. "An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer (Journal of Clinical Oncology (2007) 25 (517-525))." Journal of Clinical Oncology 30, no. 6 (2012): 678--.

Full Text

Allard, JE, Chandramouli, GVR, Stagliano, K, Hood, BL, Litzi, T, Shoji, Y, Boyd, J, Berchuck, A, Conrads, TP, Maxwell, GL, and Risinger, JI. "Analysis of PSPHL as a Candidate Gene Influencing the Racial Disparity in Endometrial Cancer. (Published online)" Front Oncol 2 (2012): 65-.

Full Text

Pearce, CL, and Berchuck, A. "Endometriosis and ovarian cancer - Authors' reply." The Lancet Oncology 13, no. 5 (2012): e190-.

Full Text

Lowery, WJ, Schildkraut, JM, Akushevich, L, Bentley, R, Marks, JR, Huntsman, D, and Berchuck, A. "Loss of ARID1A-associated protein expression is a frequent event in clear cell and endometrioid ovarian cancers." Int J Gynecol Cancer 22, no. 1 (January 2012): 9-14.

Full Text

Kelemen, LE, Wang, Q, Dinu, I, Vierkant, RA, Tsai, Y-Y, Cunningham, JM, Phelan, CM, Fridley, BL, Amankwah, EK, Iversen, ES, Berchuck, A, Schildkraut, JM, Goode, EL, and Sellers, TA. "Regular Multivitamin Supplement Use, Single Nucleotide Polymorphisms in ATIC, SHMT2, and SLC46A1, and Risk of Ovarian Carcinoma. (Published online)" Front Genet 3 (2012): 33-.

Full Text

Murphy, SK, and Berchuck, A. "Ovarian cancer progenitor/stem cells: Therapeutic potential." (December 1, 2011): 223-244. (Chapter)

Full Text

Bondurant, AE, Huang, Z, Whitaker, RS, Simel, LR, Berchuck, A, and Murphy, SK. "Quantitative detection of RASSF1A DNA promoter methylation in tumors and serum of patients with serous epithelial ovarian cancer." Gynecol Oncol 123, no. 3 (December 2011): 581-587.

Full Text

Barry, W, Chen, W, Sfakianos, G, Isner, P, Datto, M, Kuderer, N, Lyman, G, Abernethy, A, Ginsburg, G, and Berchuck, A. "A genomic-based signature of response to chemotherapy in ovarian cancer fails to predict clinical outcome in two independent cohorts." October 2011.

Full Text

Marchion, DC, Cottrill, HM, Xiong, Y, Chen, N, Bicaku, E, Fulp, WJ, Bansal, N, Chon, HS, Stickles, XB, Kamath, SG, Hakam, A, Li, L, Su, D, Moreno, C, Judson, PL, Berchuck, A, Wenham, RM, Apte, SM, Gonzalez-Bosquet, J, Bloom, GC, Eschrich, SA, Sebti, S, Chen, D-T, and Lancaster, JM. "BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival." Clin Cancer Res 17, no. 19 (October 1, 2011): 6356-6366.

Full Text

Vaughan, S, Coward, JI, Bast, RC, Berchuck, A, Berek, JS, Brenton, JD, Coukos, G, Crum, CC, Drapkin, R, Etemadmoghadam, D, Friedlander, M, Gabra, H, Kaye, SB, Lord, CJ, Lengyel, E, Levine, DA, McNeish, IA, Menon, U, Mills, GB, Nephew, KP, Oza, AM, Sood, AK, Stronach, EA, Walczak, H, Bowtell, DD, and Balkwill, FR. "Rethinking ovarian cancer: recommendations for improving outcomes. (Published online)" Nat Rev Cancer 11, no. 10 (September 23, 2011): 719-725.

Full Text

Pages